zoledronic acid + sintilimab

Zoledronic acid + sintilimab is a combination therapy that pairs a bisphosphonate (zoledronic acid) with an immune checkpoint inhibitor (sintilimab). This combination appears to be used in clinical settings for treating various advanced cancers, particularly those with bone involvement. ### Zoledronic Acid Component Zoledronic acid is a third-generation, nitrogen-containing bisphosphonate that inhibits osteoclast function and prevents bone resorption[3]. It works by binding to hydroxyapatite in bone, where it is released during bone resorption by osteoclasts. When taken up by osteoclasts, it disrupts their function by preventing the formation of podosomes (ring structures of F-actin), causing them to detach from bones and halt bone resorption[3]. It is primarily indicated for: - Treatment of hypercalcemia of malignancy - Multiple myeloma - Bone metastases from solid tumors - Osteoporosis in men and postmenopausal women - Glucocorticoid-induced osteoporosis - Paget's disease of bone[3] ### Sintilimab Component Sintilimab is a PD-1 (programmed cell death-1) inhibitor, which belongs to the class of immune checkpoint inhibitors[8]. These drugs work by blocking the PD-1 pathway, thereby enhancing T-cell immune responses against cancer cells. ### Combination Therapy Applications The combination of zoledronic acid and sintilimab appears to be used in clinical settings for: 1. **Advanced Intrahepatic Cholangiocarcinoma (ICC)**: Search results indicate this combination may have significant treatment potential for inoperable advanced ICC[8]. 2. **Intraperitoneal Treatment**: There is mention of intraperitoneal injection therapy using zoledronic acid plus sintilimab, suggesting applications in peritoneal metastases[2]. 3. **Potential Immune Enhancement**: Research suggests that bisphosphonates like zoledronic acid, when combined with immune modulators (such as thymosin α1, which is mentioned in the search results), can enhance antitumor immunity by modulating the tumor immune environment[1]. This mechanism may be relevant to the combination with sintilimab, which also works through immune modulation. The dosing mentioned in one search result indicates "zoledronic acid 0.5-1mg plus Sintilimab 1.0mg/kg"[2], though specific administration schedules are not fully detailed in the available information. This combination represents an emerging approach in cancer treatment that combines bone-targeted therapy with immunotherapy, potentially offering synergistic effects in patients with advanced cancers, particularly those with bone involvement.